Condition: Pancreatic Cancer · Sponsor: Peking Union Medical College Hospital
This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.
This description comes directly from the study's public registry record.
Taiping Zhang, doctor · +86 13520132976 · tpingzhang@yahoo.com
Always discuss trial participation with your own doctor first.
| Anhui Provincial Cancer Hospital | Hefei, Anhui, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Guangxi Medical University | Nanning, Guangxi, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Peking Unicersity First Hospital | Beijing, China | Recruiting |
| Henan Provincial People's Hospital | Henan, China | Recruiting |
| Ningbo Medical Center Lihuili Hospital | Ningbo, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
| Renji，Hospital | Shanghai, China | Recruiting |
| Wuhan Union Hospital of China | Wuhan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06375473